CytomX Therapeutics (CTMX) H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference summary

Platform innovation and pipeline overview

• Probody platform enables tumor-specific activation, improving safety and efficacy in oncology.

• Lead programs include CX-904 (masked EGFR CD3 T cell engager), CX-2051 (EpCAM-targeting ADC), and CX-801 (masked interferon alfa-2b).

• Strong partnerships with major pharma companies support development and validation.

• Multi-modality strategy includes T cell engagers, ADCs, and cytokines.

CX-904 clinical progress and data

• Phase I trial of CX-904 enrolled 35 heavily pretreated patients across multiple EGFR-expressing tumor types.

• Dose escalation reached 15 mg with step dosing, showing manageable safety profile and minimal severe rash.

• No cytokine release syndrome observed up to 10 mg; only one grade 3 rash in 35 patients.

• Encouraging anti-cancer activity in pancreatic cancer: 2 partial responses and 4 stable disease in 6 evaluable patients.

• Stable disease also observed in colorectal, lung, and esophageal cancers.

Mechanistic insights and competitive landscape

• Masking strategy enables targeting of previously undruggable EGFR/CD3 combination, reducing toxicity.

• Preclinical and clinical data show effective tumor-specific activation and minimal systemic exposure.

• Claudin 18.2 CD3 T cell engager data from Innovent at ASCO supports potential of T cell engagers in pancreatic cancer.

• Masking may further improve therapeutic window for other bispecifics.